# A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

> **NCT00884507** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 389 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO5313534
- **DRUG:** RO5313534
- **DRUG:** RO5313534

## Key facts

- **NCT ID:** NCT00884507
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 389 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884507, "A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00884507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*